K Number
K972886
Device Name
MIRAGE
Manufacturer
Date Cleared
1997-10-01

(57 days)

Product Code
Regulation Number
892.2050
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Mirage system is indicated for the acquisition, formatting and storage of scintigraphy camera output data. It is capable of processing and displaying the acquired information in traditional formats, as well as in pseudo three-dimensional renderings, and in various forms of animated sequences, showing kinetic attributes of the imaged organs.
Device Description
The product (Mirage) is basically a camera driven acquisition, processing and postprocessing (visualization and analysis) software system with a Patient Data Management system, to which minimal processing (e.g. tomographic reconstruction) has been added.
More Information

Not Found

No
The summary describes traditional image processing and data management, with no mention of AI or ML terms, training data, or performance metrics typically associated with AI/ML devices.

No
The device is described as a software system for acquiring, processing, and displaying scintigraphy camera data. Its intended use focuses on data management, processing, and visualization for diagnostic purposes rather than directly treating a disease or condition.

No
The device is described as a system for acquiring, formatting, processing, and storing scintigraphy camera output data, and for displaying this information. While it processes medical images for physicians, its stated purpose does not include diagnosing a condition, but rather presenting data to aid a Nuclear Physician.

Yes

The device description explicitly states "The product (Mirage) is basically a camera driven acquisition, processing and postprocessing (visualization and analysis) software system". While it interacts with a camera, the device itself is described as a software system.

Based on the provided information, the Mirage system is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Mirage System Function: The Mirage system processes and displays data acquired directly from a scintigraphy camera. This data represents the distribution of a radioactive tracer within the patient's body, not a sample taken from the body.
  • Input Data: The input is "scintigraphy camera output data," which is an imaging modality, not a biological sample.
  • Intended Use: The intended use is for "acquisition, formatting and storage of scintigraphy camera output data," and "processing and displaying the acquired information." This is focused on image processing and visualization of in-vivo data.

Therefore, the Mirage system falls under the category of medical imaging software, not in vitro diagnostics.

N/A

Intended Use / Indications for Use

The intended use of the Mirage system of image acquisition, processing and analysis is to provide the Nuclear Physician with a tool to acquire, format and store the data acquired by a camera, to display in all the traditional manners, to add three-dimensional renderings to the displays, and to display some kinetic attributes of the imaged organs or systems. The major benefits are the ease of use, the speed of processing, and the variety of display alternatives.

The Mirage system is indicated for the acquisition, formatting and storage of scintigraphy camera output data. It is capable of processing and displaying the acquired information in traditional formats, as well as in pseudo three-dimensional renderings, and in various forms of animated sequences, showing kinetic attributes of the imaged organs.

Product codes (comma separated list FDA assigned to the subject device)

LLZ

Device Description

Camera driven acquisition software refers to the formatting of camera signals into spatial distributions, and producing timing signals allowing camera defined acquisition or motion to proceed. The term processing refers to all manners of data manipulation, following the acquisition. including the reconstruction of tomographic volume data from multiple projection acquisitions. The term post-processing refers to image manipulation and analysis which occurs after the image (planar or tomographic, static or dynamic) has been formed. Post-processing specifically includes display methods, which determine how the user can (re)view and interpret the data.

The most crucial component for a post-processing system, which should be able to receive and handle data (images) from different origins (acquisition systems), is the Patient Data Management.

The product (Mirage) is basically a camera driven acquisition, processing and postprocessing (visualization and analysis) software system with a Patient Data Management system, to which minimal processing (e.g. tomographic reconstruction) has been added.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Scintigraphy camera output data (Nuclear Medicine Planar and SPECT Image)

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Nuclear Physician

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Substantial equivalence was shown non-clinically by demonstrating that Generic Image Operations, Generic Tomographic post-processing, First Pass Ventriculography and Planar Gated Blood-pool Analysis did not yield substantially different results from those of the predicate devices.

Substantial equivalence was evidenced clinically by demonstrating that in the clinical applications (of current clinical cases or archival cases) the clinician's conclusion would not have differed substantially.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K914350, K913641

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 892.2050 Medical image management and processing system.

(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).

0

Segami Corporation

×972886

10. 510K Summary

OCT - 1 1997

10.1. Identification

ﻟﻤﺴﺘﻘ

10.1.1 Date of Application:

10.1.2 Manufacturing Facility:

August 4, 1997

Segami Corporation, Inc. 12624 Golden Oak Drive Ellicott City, MD 21042 phone: (410) 531-2357 fax: (410) 531-5029

10.1.3 Contact Person :

Philippe Briandet Ph.D. 12624 Golden Oak Drive Ellicott City, MD 21042 phone: (410) 531-2357 fax: (410) 531-5029

10.1.4 Signature

Philippe Briander

Date 08-04-97

1

10. 2. Device Name

ﻴﺔ ﺍﻟﻤﺴﺘﻘﻠﺔ ﺍﻟﻤ

10.2.1 Classification Name:

10.2.2 Common/Usual Name:

Image Processing System

Nuclear Medicine Planar and SPECT Image Processing Software

10.2.3 Proprietary Name:

MIRAGE

10.3. Substantial Equivalence (Predicate devices)

The predicate devices are the ICON COMPUTER SYSTEM by Siemens Medical Systems, Inc.(Product code JWM, 510K # K914350) and SOPHY NXT by Sopha Medical Systems, Inc.(product code KPS and 501K# K913641).

Substantial equivalence was shown non-clinically by demonstrating that Generic Image Operations, Generic Tomographic post-processing, First Pass Ventriculography and Planar Gated Blood-pool Analysis did not yield substantially different results from those of the predicate devices.

Substantial equivalence was evidenced clinically by demonstrating that in the clinical applications (of current clinical cases or archival cases) the clinician's conclusion would not have differed substantially.

The technological characteristics which differ have no effect on the software's results: The Mirage system is based on the PC architecture (versus Macintosh and proprietary for predicate devices), the operating system is Windows NT (versus Macintosh and Forth), the software language is Visual C++ (versus Pascal and Forth).

The Patient Data Management went through a separate technical test in which the validity and integrity of the data was evaluated.

Conclusion:

The Mirage Software package is closely similar in intended use and technical characteristics to the predicate devices. The product raises no new questions regarding safety or effectiveness. Segami Corporation. Inc. concludes that the product is essentially equivalent to devices of the same classification previously approved.

2

10.4 Description.

Camera driven acquisition software refers to the formatting of camera signals into spatial distributions, and producing timing signals allowing camera defined acquisition or motion to proceed. The term processing refers to all manners of data manipulation, following the acquisition. including the reconstruction of tomographic volume data from multiple projection acquisitions. The term post-processing refers to image manipulation and analysis which occurs after the image (planar or tomographic, static or dynamic) has been formed. Post-processing specifically includes display methods, which determine how the user can (re)view and interpret the data.

The most crucial component for a post-processing system, which should be able to receive and handle data (images) from different origins (acquisition systems), is the Patient Data Management.

The product (Mirage) is basically a camera driven acquisition, processing and postprocessing (visualization and analysis) software system with a Patient Data Management system, to which minimal processing (e.g. tomographic reconstruction) has been added.

10.5 Statement of Indication for use.

The intended use of the Mirage system of image acquisition, processing and analysis is to provide the Nuclear Physician with a tool to acquire, format and store the data acquired by a camera, to display in all the traditional manners, to add three-dimensional renderings to the displays, and to display some kinetic attributes of the imaged organs or systems. The major benefits are the ease of use, the speed of processing, and the variety of display alternatives.

3

Image /page/3/Picture/0 description: The image shows a logo for the Department of Health & Human Services. The logo consists of a stylized human figure with three arms raised in a wave-like pattern. The text "DEPARTMENT OF HEALTH &" is arranged vertically along the left side of the logo.

Food and Drug Administration -9200 Corporate Boulevard Rockville MD 20850

Philippe Briandet, Ph.D. President Segami Corporation 12624 Golden Oak Drive Ellicott City, MD 21042

OCT - I 1997 Re: K972886 Mirage Nuclear Medicine Image Processing System Dated: August 4, 1997 Received: August 5, 1997 Unclassified/Procode: 90 LLZ

Dear Dr. Briandet:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Pracice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for question and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

h.J.Liau Yin
Lillian Yin, Ph.D.

Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

510(k) Number (if known):_ K972886

Device Name: Mirage

Indications for Use:

The Mirage system is indicated for the acquisition, formatting and storage of scintigraphy camera output data. It is capable of processing and displaying the acquired information in traditional formats, as well as in pseudo three-dimensional renderings, and in various forms of animated sequences, showing kinetic attributes of the imaged organs.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Thavid A. Seymore

(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number .

Prescription Use (Per 21 CFR 801.109) OR

Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________

(Optional Format 1-2-96)